Tags

Type your tag names separated by a space and hit enter

The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries.
Vaccine. 2008 Nov 25; 26(50):6305-16.V

Abstract

The burden of typhoid fever remains high in impoverished settings, and increasing antibiotic resistance is making treatment costly. One strategy for reducing the typhoid morbidity and mortality is vaccination with the Vi polysaccharide vaccine. We use a wealth of new economic and epidemiological data to evaluate the cost-effectiveness of Vi vaccination against typhoid in sites in four Asian cities: Kolkata (India), Karachi (Pakistan), North Jakarta (Indonesia), and Hue (Vietnam). We report results from both a societal as well as a public sector financial perspective. Baseline disease burden estimates in the four areas are: 750 cases per year in two Kolkata neighborhoods (pop 185,000); 84 cases per year in the city of Hue (pop 280,000); 298 cases per year in two sub-districts in North Jakarta (pop 161,000), and 538 cases per year in three squatter settlements in Karachi (pop 102,000). We estimate that a vaccination program targeting all children (2-14.9) would prevent 456, 158, and 258 typhoid cases (and 4.6, 1.6, and 2.6 deaths), and avert 126, 44, and 72 disability-adjusted life years (DALYs) over 3 years in Kolkata, North Jakarta and Karachi, respectively. The net social costs would be US$160 and US$549, per DALY averted in Kolkata and North Jakarta, respectively. These programs, along with a similar program in Karachi, would be considered "very cost-effective" (e.g. costs per DALY averted less than per capita gross national income (GNI)) under a wide range of assumptions. Community-based vaccination programs that also target adults in Kolkata and Jakarta are less cost-effective because incidence is lower in adults than children, but are also likely to be "very cost-effective". A program targeting school-aged children in Hue, Vietnam would prevent 21 cases, avert 6 DALYs, and not be cost-effective (US$3779 per DALY averted) because of the low typhoid incidence there.

Authors+Show Affiliations

Evans School of Public Affairs, University of Washington, Box 353055, Seattle, WA 98195-3055, USA. jhcook@u.washington.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18835415

Citation

Cook, Joseph, et al. "The Cost-effectiveness of Typhoid Vi Vaccination Programs: Calculations for Four Urban Sites in Four Asian Countries." Vaccine, vol. 26, no. 50, 2008, pp. 6305-16.
Cook J, Jeuland M, Whittington D, et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine. 2008;26(50):6305-16.
Cook, J., Jeuland, M., Whittington, D., Poulos, C., Clemens, J., Sur, D., Anh, D. D., Agtini, M., & Bhutta, Z. (2008). The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine, 26(50), 6305-16. https://doi.org/10.1016/j.vaccine.2008.09.040
Cook J, et al. The Cost-effectiveness of Typhoid Vi Vaccination Programs: Calculations for Four Urban Sites in Four Asian Countries. Vaccine. 2008 Nov 25;26(50):6305-16. PubMed PMID: 18835415.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. AU - Cook,Joseph, AU - Jeuland,Marc, AU - Whittington,Dale, AU - Poulos,Christine, AU - Clemens,John, AU - Sur,Dipika, AU - Anh,Dang Duc, AU - Agtini,Magdarina, AU - Bhutta,Zulfiqar, AU - ,, Y1 - 2008/10/07/ PY - 2008/03/31/received PY - 2008/09/09/revised PY - 2008/09/15/accepted PY - 2008/10/7/pubmed PY - 2009/2/10/medline PY - 2008/10/7/entrez SP - 6305 EP - 16 JF - Vaccine JO - Vaccine VL - 26 IS - 50 N2 - The burden of typhoid fever remains high in impoverished settings, and increasing antibiotic resistance is making treatment costly. One strategy for reducing the typhoid morbidity and mortality is vaccination with the Vi polysaccharide vaccine. We use a wealth of new economic and epidemiological data to evaluate the cost-effectiveness of Vi vaccination against typhoid in sites in four Asian cities: Kolkata (India), Karachi (Pakistan), North Jakarta (Indonesia), and Hue (Vietnam). We report results from both a societal as well as a public sector financial perspective. Baseline disease burden estimates in the four areas are: 750 cases per year in two Kolkata neighborhoods (pop 185,000); 84 cases per year in the city of Hue (pop 280,000); 298 cases per year in two sub-districts in North Jakarta (pop 161,000), and 538 cases per year in three squatter settlements in Karachi (pop 102,000). We estimate that a vaccination program targeting all children (2-14.9) would prevent 456, 158, and 258 typhoid cases (and 4.6, 1.6, and 2.6 deaths), and avert 126, 44, and 72 disability-adjusted life years (DALYs) over 3 years in Kolkata, North Jakarta and Karachi, respectively. The net social costs would be US$160 and US$549, per DALY averted in Kolkata and North Jakarta, respectively. These programs, along with a similar program in Karachi, would be considered "very cost-effective" (e.g. costs per DALY averted less than per capita gross national income (GNI)) under a wide range of assumptions. Community-based vaccination programs that also target adults in Kolkata and Jakarta are less cost-effective because incidence is lower in adults than children, but are also likely to be "very cost-effective". A program targeting school-aged children in Hue, Vietnam would prevent 21 cases, avert 6 DALYs, and not be cost-effective (US$3779 per DALY averted) because of the low typhoid incidence there. SN - 0264-410X UR - https://www.unboundmedicine.com/medline/citation/18835415/The_cost_effectiveness_of_typhoid_Vi_vaccination_programs:_calculations_for_four_urban_sites_in_four_Asian_countries_ DB - PRIME DP - Unbound Medicine ER -